MLTX — MoonLake Immunotherapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike
MoonLake soars as FDA clears path for skin disease drug filing
Brief: Moonlake Immunotherapeutics Announces Positive Outcome From Type B Meeting With U.S. FDA
Brief: MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
MoonLake Immunotherapeutics' Q3 net loss widens
Brief: MoonLake Immunotherapeutics Q3 EPS USD -1.1
MoonLake Immunotherapeutics plunges after disappointing data from key skin drug trials
UCB at record high after competitor's skin disease drug data
Brief: Moonlake Immunotherapeutics Reports On Week 16 Results Of The Vela Phase 3 Hidradenitis Suppurativa Program With The Nanobody® Sonelokimab
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
Brief: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results And Provides A Business Update
MoonLake Immunotherapeutics's Q2 net loss widens
Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports (updated)
Deals of the day-Mergers and acquisitions
MoonLake climbs after report of Merck buyout talks
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports (updated)
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports